Cowen reaffirmed their hold rating on shares of Regeneron Pharmaceuticals (NASDAQ:REGN) in a research note published on Monday, January 7th. Cowen currently has a $385.00 price target on the biopharmaceutical company’s stock.
A number of other research firms also recently issued reports on REGN. Zacks Investment Research downgraded Regeneron Pharmaceuticals from a hold rating to a sell rating in a research note on Saturday, January 5th. Guggenheim upgraded Regeneron Pharmaceuticals from a neutral rating to a buy rating and set a $461.00 price target for the company in a research note on Friday, January 4th. ValuEngine upgraded Regeneron Pharmaceuticals from a sell rating to a hold rating in a research note on Saturday, December 15th. Goldman Sachs Group upgraded Regeneron Pharmaceuticals from a neutral rating to a conviction-buy rating in a research note on Thursday, December 13th. Finally, BidaskClub upgraded Regeneron Pharmaceuticals from a hold rating to a buy rating in a research note on Tuesday, December 11th. Two research analysts have rated the stock with a sell rating, fourteen have given a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the stock. The company has an average rating of Hold and a consensus price target of $404.11.
NASDAQ REGN traded up $0.88 during trading hours on Monday, hitting $430.15. The company’s stock had a trading volume of 702,900 shares, compared to its average volume of 803,191. Regeneron Pharmaceuticals has a 12 month low of $281.89 and a 12 month high of $431.32. The company has a market capitalization of $46.45 billion, a price-to-earnings ratio of 32.08, a PEG ratio of 1.81 and a beta of 1.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.30 and a current ratio of 4.04.
Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 EPS for the quarter, topping the consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The company had revenue of $1.66 billion during the quarter, compared to the consensus estimate of $1.64 billion. During the same period last year, the company earned $3.99 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.8% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals will post 18.88 earnings per share for the current fiscal year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 1,791 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, January 10th. The stock was sold at an average price of $410.00, for a total value of $734,310.00. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at approximately $5,786,740. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Christopher R. Fenimore sold 1,848 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Thursday, December 20th. The stock was sold at an average price of $358.97, for a total value of $663,376.56. Following the completion of the sale, the vice president now directly owns 9,871 shares in the company, valued at approximately $3,543,392.87. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 3,645 shares of company stock worth $1,399,980. Insiders own 12.42% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. Rehmann Capital Advisory Group increased its stake in Regeneron Pharmaceuticals by 1,700.0% in the 3rd quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 68 shares during the last quarter. Intercontinental Wealth Advisors LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $33,000. We Are One Seven LLC bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $87,000. Ledyard National Bank bought a new stake in Regeneron Pharmaceuticals in the 4th quarter worth approximately $90,000. Finally, Shine Investment Advisory Services Inc. increased its stake in Regeneron Pharmaceuticals by 104.1% in the 4th quarter. Shine Investment Advisory Services Inc. now owns 298 shares of the biopharmaceutical company’s stock worth $111,000 after acquiring an additional 152 shares during the last quarter. 67.25% of the stock is currently owned by institutional investors and hedge funds.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Read More: How mutual funds make money
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.